Compare · CI vs MDXH
CI vs MDXH
Side-by-side comparison of The Cigna Group (CI) and MDxHealth SA (MDXH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CI and MDXH operate in Medical Specialities (Health Care), so they compete in similar markets.
- CI is the larger of the two at $78.96B, about 1370.9x MDXH ($57.6M).
- Over the past year, CI is down 1.6% and MDXH is down 95.0% - CI leads by 93.4 points.
- Both names hit the wire about 5 times in the past 4 weeks.
- CI has more recent analyst coverage (25 ratings vs 7 for MDXH).
- Company
- The Cigna Group
- MDxHealth SA
- Price
- -
- -
- Market cap
- $78.96B
- $57.6M
- 1M return
- +9.55%
- -69.62%
- 1Y return
- -1.62%
- -95.01%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 5
- 5
- Recent ratings
- 25
- 7
The Cigna Group
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
MDxHealth SA
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
Latest CI
- SEC Form 8-K filed by The Cigna Group
- The Cigna Group's Third Quarter 2026 Earnings Release Details
- Cigna Healthcare Introduces Health Sense To Connect Guidance, Benefits and Clinical Support Around Each Person, Improving Affordability and Outcomes
- The Cigna Group filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- The Cigna Group Hosts 2026 Investor Day; Introduces "Lead to One" to Drive Durable Growth Through Complex Care Leadership and Differentiated Capabilities
- Is Volunteering Good for Your Health? New Research From The Cigna Group Finds a Strong Connection
- Evercore ISI initiated coverage on The Cigna Group with a new price target
- The Cigna Group to Host Investor Day on September 30
- Officer Neville Everett sold $175,259 worth of shares (617 units at $284.05) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 5,053 units (SEC Form 4)
- Officer Evanko Brian C was granted 3,113 shares, increasing direct ownership by 8% to 41,030 units (SEC Form 4)
Latest MDXH
- MDxHealth SA downgraded by Lake Street with a new price target
- MDxHealth SA downgraded by Craig Hallum
- SEC Form 6-K filed by MDxHealth SA
- Amendment: SEC Form SCHEDULE 13D/A filed by MDxHealth SA
- MDxHealth Announces Preliminary Third Quarter 2026 Revenue and Suspends Full-Year 2026 Revenue Guidance
- SEC Form 144 filed by MDxHealth SA
- SEC Form 6-K filed by MDxHealth SA
- Amendment: SEC Form SCHEDULE 13G/A filed by MDxHealth SA
- Director Mvm Partners, Llc bought $1,000,000 worth of Ordinary Shares (2,202,643 units at $0.45) (SEC Form 4)
- SEC Form SCHEDULE 13D filed by MDxHealth SA